# 哮喘疾病市场

> 哮喘疾病市场研究报告按治疗类型（控制药物、救援药物、生物制剂、联合疗法）、按哮喘原因（过敏性哮喘、非过敏性哮喘、运动诱发性哮喘、职业性哮喘）、按严重程度（轻度间歇性、轻度持续性、中度持续性、重度持续性）、按年龄组（儿童、青少年、成人、老年人）以及按地区（北美、欧洲、南美、亚太、中东和非洲）- 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 3.52%
- **2024:** $ 26.22 Billion
- **2025:** $ 27.14 Billion
- **2035:** $ 38.36 Billion
- **Key Players:** GlaxoSmithKline (GB), AstraZeneca (GB), Boehringer Ingelheim (DE), Novartis (CH), Teva Pharmaceutical Industries (IL), Sanofi (FR), Merck & Co. (US), Pfizer (US), Roche (CH)

**Report ID:** MRFR/HC/32413-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/asthma-disease-market-34260

---

## Market Summary

## **Global Asthma Disease Market Overview**

As per MRFR analysis, the Asthma Disease Market Size was estimated at 26.22 (USD Billion) in 2024. The Asthma Disease Market Industry is expected to grow from 27.14 (USD Billion) in 2025 to 37.06 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 3.52% during the forecast period (2025 - 2034).

### **Key Asthma Disease Market Trends Highlighted**

The Asthma Disease Market is influenced by several key market drivers that contribute to its growth. Increasing prevalence of asthma, driven by factors such as urbanization, pollution, and changing lifestyle patterns, plays a significant role in expanding the market. Awareness campaigns focusing on prevention and management of asthma also significantly contribute to the demand for effective treatment options. Additionally, advancements in healthcare technology and the development of new medications and inhalation devices enhance the treatment landscape, providing patients with more effective management solutions. Opportunities abound in the market, particularly in the areas of personalized medicine and telehealth services.

he rise of digital health solutions presents a chance for companies to create innovative treatments and management tools tailored to individual patient needs. Furthermore, there is potential for growth in emerging economies where access to healthcare services is expanding. Developing new formulations and delivery methods can also capture interest in regions with unmet medical needs, thus marking significant opportunities for investment and innovation. In recent times, trends have shown a shift towards preventive care and an emphasis on patient education to improve disease management. 

The integration of artificial intelligence and data analytics into asthma management platforms is becoming increasingly important, allowing for better tracking of patient symptoms and adherence to treatment plans.There is also a growing interest in biological therapies that target specific inflammation pathways in asthma, offering alternatives to traditional medications. This evolution in treatment options reflects a broader understanding of asthma and demonstrates a trend towards more customized and effective approaches in managing the disease, ultimately improving patient outcomes.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **Asthma Disease Market Drivers**

### **Increasing Prevalence of Asthma**

The rising prevalence of asthma globally is a critical driver for the Asthma Disease Market Industry. With urbanization and changes in lifestyle leading to higher rates of respiratory diseases, healthcare systems are increasingly focusing on asthma management. The increased diagnosis and awareness of asthma conditions have resulted in larger patient populations requiring ongoing treatment. This growing patient base is pushing significant advancements in therapeutic solutions and management strategies, which is incredibly beneficial for market stakeholders.

Furthermore, the aging population is more susceptible to chronic respiratory diseases, including asthma, contributing to a higher overall market demand. As the market is expected to be valued significantly higher in the future, it reflects the urgency to address asthma with effective treatment options. Innovations in medication and treatment protocols are increasingly critical in this market. Many pharmaceutical companies are exploring new therapeutic alternatives and delivery methods to enhance the quality of life for patients.Researchers are developing targeted therapies and preventive measures that address not only the symptoms but also the underlying causes of asthma.

As clinicians become more knowledgeable about asthma management, it leads to better patient outcomes and aids in market growth.

The increased emphasis on personalized medicine also enhances treatment efficacy, making it easier for patients to adhere to their prescribed therapies. In the long term, the continuous evaluation of asthma management guidelines will shape the landscape of the Asthma Disease Market Industry, contributing to novel interventions and improved health systems.

### **Advancements in Treatment Options**

One of the significant drivers in the Asthma Disease Market Industry is the rapid advancement in treatment options for asthma. Innovative therapies such as biologics have emerged, offering targeted treatment strategies that provide more effective control of asthma symptoms. These advancements not only enhance treatment efficacy but also improve patient adherence to therapy regimens, thus supporting long-term market growth.

As more research is focused on understanding the pathophysiology of asthma, new drugs and therapies are being developed that target specific pathways involved in the condition.This exploration and subsequent development of more potent combinations and customized asthma medications have a profound impact on patient outcomes.

### **Growing Awareness and Education**

Increased awareness and education about asthma management play vital roles in driving the Asthma Disease Market Industry.

As public health campaigns advocate for a better understanding of asthma, individuals are becoming more familiar with the symptoms and the importance of proper management strategies. This heightened awareness leads to earlier diagnosis and treatment, which is crucial for optimal management of asthma. Educational initiatives targeting both patients and healthcare professionals contribute to improved knowledge, ultimately resulting in better health outcomes and a growing market.

## **Asthma Disease Market Segment Insights**

### **Asthma Disease Market Treatment Type Insights  **

The Asthma Disease Market is characterized by various treatment types, which play a crucial role in managing asthma symptoms and improving patients' quality of life. In 2023, the market's total revenue reached 24.46 USD Billion, with expectations to grow to 33.4 USD Billion by 2032, reflecting steady development in treatment methodologies.

Within this dynamic landscape, Controller Medications emerge as a dominant force, valued at 10.0 USD Billion in 2023 and projected to climb to 13.5 USD Billion in 2032. This segment holds majority significance as it focuses on long-term management and prevention of asthma attacks, making it essential for patients who need to maintain control over their condition.

On the other hand, Rescue Medications also play an important role in the asthma treatment landscape, recording a valuation of 6.5 USD Billion in 2023, with an increase to 8.5 USD Billion anticipated by 2032. These medications are critical for patients experiencing acute asthma symptoms, providing rapid relief and underscoring the importance of immediate intervention during attacks.

Biologics, valued at 4.0 USD Billion in 2023, are gaining traction as innovative therapies that target specific pathways involved in asthma, projecting a valuation of 6.5 USD Billion by 2032. This growing sub-segment offers tailored treatment options and presents a significant leap in managing severe asthma cases.

Moreover, [Aesthetics Combination Therapy](../../../reports/aesthetics-combination-therapy-market-23964)valued at 4.96 USD Billion in 2023 and expected to rise modestly to 5.0 USD Billion by 2032, integrates multiple mechanisms of action to provide comprehensive management of asthma, catering to patients with complex needs. It is vital for optimizing treatment effectiveness and minimizing side effects, thereby enhancing patient compliance.

The Asthma Disease Market segmentation showcases diverse treatment types that not only accommodate different patient requirements but also reflect ongoing advancements in asthma management strategies. The growth of these segments is driven by increasing asthma prevalence, heightened awareness of available treatments, and ongoing innovations in drug formulations and delivery methods.

However, challenges persist, including the need for enhanced patient education, accessibility to treatments, and addressing the high cost of advanced therapies such as biologics. Overall, the interplay between these treatment types not only shapes the current market landscape but also identifies future opportunities for growth and improvement within the Global Asthma Disease Market.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

### **Asthma Disease Market Cause of Asthma Insights  **

The Asthma Disease Market is currently valued at 24.46 billion USD in 2023 and is witnessing a steady growth trajectory driven by various factors, including rising pollution and increasing prevalence of allergens. The market shows a diverse segmentation around the cause of asthma, prominently featuring Allergic Asthma, Non-Allergic Asthma, Exercise-Induced Asthma, and Occupational Asthma. Allergic Asthma is notable for being one of the most common forms triggered by airborne substances such as pollen and dust. 

Non-allergic asthma, while less common, significantly contributes to the market landscape as respiratory infections, stress, or physical activities cause it.Exercise-induced asthma typically impacts individuals during physical exertion, making it an essential area of focus for athletic populations. Occupational Asthma emerges from workplace irritants, highlighting the need for specific preventive and therapeutic measures in various industries.

Understanding these causes and their prevalence provides critical insights into the Asthma Disease Market data, showcasing the necessity for targeted treatments and market growth potential in addressing the specific needs of asthma sufferers.

### **Asthma Disease Market Severity Insights  **

The Global Asthma Disease Market, with a valuation of 24.46 billion USD in 2023, has shown notable segmentation in terms of severity, highlighting its essential role in understanding treatment approaches and patient management strategies. The severity of asthma can be categorized into various classifications, with Mild Intermittent and Mild Persistent presenting a considerable portion of the overall patient population, indicating a significant need for effective management solutions in these areas.

Moderate Persistent asthma accounts for a substantial share as well, reflecting a critical segment requiring sustained treatment to maintain control and minimize exacerbations.Severe Persistent asthma dominates the severity landscape due to its higher healthcare resource consumption and complexity in management, necessitating advanced therapies and personalized treatment plans.

The Asthma Disease Market statistics suggest that changes in lifestyle, environmental factors, and urbanization trends continue to drive the prevalence of asthma, further emphasizing the market's growth potential. Therefore, understanding the Asthma Disease Market segmentation around severity aids in addressing individual patient needs and tailoring innovations effectively to manage asthma in various severity levels.The trends in healthcare spending and increased awareness about asthma management are expected to catalyze market growth in the coming years.

### **Asthma Disease Market Age Group Insights  **

The Asthma Disease Market revenue is significantly influenced by the age group segmentation, which encompasses Children, Adolescents, Adults, and the Elderly. In 2023, the market is valued at 24.46 USD Billion, showcasing substantial importance across various age demographics.

Each age group presents different challenges and treatment approaches, ultimately driving market growth. For instance, the Children and Adolescents segments are crucial because of the rising incidence of asthma among young individuals, emphasizing the need for tailored management solutions.Adults constitute a major portion of the Asthma Disease Market statistics, reflecting an increased awareness and diagnosis of asthma, while the Elderly group adds complexity due to comorbidities, necessitating specialized treatments. The increasing prevalence of asthma, along with advancements in inhalation therapy and patient education, are notable growth drivers for this market.

 However, challenges such as environmental factors and adherence to therapies persist, requiring constant innovation and strategic planning within the Asthma Disease Market industry to meet diverse needs across all age groups.The Asthma Disease Market data indicates that addressing these factors is pivotal to sustaining market development and ensuring effective asthma management for all age demographics.

### **Asthma Disease Market Regional Insights  **

The Asthma Disease Market achieved a valuation of 24.46 USD Billion in 2023, with notable contributions from various regions. North America held a majority share, valued at 10.5 USD Billion, and is expected to grow to 14.2 USD Billion by 2032, driven by advanced healthcare infrastructure and rising asthma prevalence.

Europe followed with a significant valuation of 6.8 USD Billion in 2023, growing to 9.2 USD Billion, reflecting increased awareness and treatment adoption. The APAC region, valued at 4.5 USD Billion in 2023, is set to reach 6.1 USD Billion, bolstered by growing populations and rising healthcare expenditure.Meanwhile, South America and MEA showcase smaller but important markets, valued at 1.3 USD Billion and 1.36 USD Billion, respectively, in 2023. Their growth potential stems from improving healthcare access and increasing the prevalence of asthma.

Across these regions, the Asthma Disease Market revenue trends indicate a continued focus on innovation in treatment and management, as well as addressing environmental factors contributing to asthma.

**Source: Primary Research, Secondary Research, MRFR Database and Analyst Review**

## **Asthma Disease Market Key Players and Competitive Insights**

The Asthma Disease Market is characterized by a diverse and competitive landscape where numerous pharmaceutical and biotechnology companies are striving to innovate and deliver effective treatment options. This sector is increasingly driven by a rise in asthma prevalence, advancements in treatment protocols, and greater awareness among patients and healthcare providers regarding asthma management. 

The competitive insights reveal that companies are focusing on developing biologics, incremental advancements in inhaler technology, and personalized medicine to cater to the varying needs of asthma patients. As competition intensifies, firms are enhancing their research and development efforts to offer targeted therapies designed specifically for different asthma phenotypes while also grappling with the complexities of regulatory approvals and market access challenges.AstraZeneca has emerged as a formidable player in the Global Asthma Disease Market, leveraging its extensive portfolio of respirable therapies and biologics. 

The company has positioned itself as a leader through its strategic investments in research and development, yielding groundbreaking treatments that address both mild and severe asthma. One of the defining strengths of AstraZeneca is its commitment to innovative delivery systems, which include advanced inhalers that improve medication adherence and patient outcomes. Furthermore, the company has established robust collaborations with research institutions and healthcare systems to enhance patient education and disease management.

AstraZeneca's strong presence in both developed and emerging markets further solidifies its competitive edge, as it provides diversified access to its therapies, ensuring that more patients benefit from its leading treatment options.

Sanofi is another key competitor within the Global Asthma Disease Market, recognized for its comprehensive approach to addressing asthma through a broad range of products. The company's strengths lie in its well-established presence in the biologics segment, demonstrating efficacy in treating severe asthma. Sanofi emphasizes patient-centric solutions by integrating patient support programs that enhance medication adherence and foster better disease management practices. 

Furthermore, the company boasts a strong pipeline of innovative drugs, including various monoclonal antibodies targeting specific asthma pathways, which positions it well to meet the evolving treatment demands. Sanofi's collaborative efforts with healthcare professionals and patient advocacy groups further amplify its reach in the market, enabling the company to understand better and respond to patient needs while enhancing its competitive position in the asthma therapeutic landscape.

## **Key Companies in the Asthma Disease Market Include**

- **[AstraZeneca](https://www.astrazeneca.com/our-therapy-areas/respiratory-and-immunology.html)**
- Sanofi
- Merck and  Co
- Eli Lilly and Company
- Teva Pharmaceutical Industries
- Boehringer Ingelheim
- Mylan
- Bristol-Myers Squibb
- Pfizer
- Johnson and  Johnson
- Roche
- Novartis
- Amgen
- GlaxoSmithKline

## Asthma Disease Market Industry Developments

- **Q2 2024: AstraZeneca’s Airsupra asthma drug wins U.S. FDA approval** AstraZeneca and Avillion announced that the U.S. Food and Drug Administration approved Airsupra (albuterol/budesonide), a new rescue inhaler for asthma, marking a significant addition to the company’s respiratory portfolio.
- **Q2 2024: GSK receives European Commission approval for Trelegy Ellipta in pediatric asthma** GlaxoSmithKline announced that the European Commission approved Trelegy Ellipta for the treatment of asthma in children aged 6 to 11, expanding the drug’s label in the EU.
- **Q1 2024: Amgen and AstraZeneca Announce FDA Approval of TEZSPIRE® (tezepelumab-ekko) for Self-Administration in Severe Asthma** Amgen and AstraZeneca received FDA approval for a new pre-filled, single-use pen for TEZSPIRE, allowing patients with severe asthma to self-administer the biologic therapy at home.
- **Q2 2024: Sanofi and Regeneron’s Dupixent® approved by FDA as first biologic for children aged 1 to 11 years with eosinophilic asthma** Sanofi and Regeneron announced FDA approval of Dupixent for children aged 1 to 11 years with eosinophilic asthma, making it the first biologic approved for this age group in the U.S.
- **Q1 2024: Propeller Health and Novartis Announce Partnership to Integrate Digital Health Platform with Asthma Inhalers** Propeller Health and Novartis entered a partnership to integrate Propeller’s digital health platform with Novartis’ asthma inhalers, aiming to improve medication adherence and patient outcomes.
- **Q2 2024: BioMed X launches new research program with Boehringer Ingelheim to develop novel therapies for asthma** BioMed X and Boehringer Ingelheim announced the launch of a joint research program focused on discovering new therapeutic approaches for asthma.
- **Q1 2024: Pulmatrix Announces Positive Topline Results from Phase 2 Study of PUR1900 in Asthma** Pulmatrix reported positive topline results from its Phase 2 clinical trial evaluating PUR1900, an inhaled antifungal, in patients with asthma, supporting further development of the candidate.
- **Q2 2024: Vectura Fertin Pharma opens new inhalation manufacturing facility in the UK** Vectura Fertin Pharma announced the opening of a new manufacturing facility dedicated to the production of inhaled therapies, including asthma treatments, in Chippenham, UK.
- **Q1 2024: Kinaset Therapeutics Raises $45 Million Series B Financing to Advance Asthma Drug Candidate** Kinaset Therapeutics closed a $45 million Series B financing round to support the clinical development of its lead asthma drug candidate, KN-002.
- **Q2 2024: Verona Pharma’s ensifentrine receives positive CHMP opinion for maintenance treatment of COPD and asthma** Verona Pharma announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for ensifentrine, supporting its approval for maintenance treatment of COPD and asthma.
- **Q1 2024: AstraZeneca and Honeywell partner to develop next-generation inhalers with near-zero global warming potential propellants** AstraZeneca and Honeywell announced a partnership to develop next-generation inhalers for asthma and COPD using Honeywell’s near-zero global warming potential propellants.
- **Q2 2024: Amgen appoints new head of respiratory and inflammation R&D** Amgen announced the appointment of a new executive to lead its respiratory and inflammation research and development division, overseeing the company’s asthma and allergy pipeline.

## **Asthma Disease Market Segmentation Insights**

### **Asthma Disease Market Treatment Type Outlook**

- Controller Medications
- Rescue Medications
- Biologics
- Combination Therapy

### **Asthma Disease Market Cause of Asthma Outlook**

- Allergic Asthma
- Non-Allergic Asthma
- Exercise-Induced Asthma
- Occupational Asthma

### **Asthma Disease Market Severity Outlook**

- Mild Intermittent
- Mild Persistent
- Moderate Persistent
- Severe Persistent

### **Asthma Disease Market Age Group Outlook**

- Children
- Adolescents
- Adults
- Elderly

### **Asthma Disease Market Regional Outlook**

- North America
- Europe
- South America
- Asia-Pacific
- Middle East and Africa 

## Market Drivers

### 提高意识和教育

对哮喘的认识和教育的提高是哮喘疾病市场的重要驱动因素。公共卫生宣传和教育活动显著提高了人们对哮喘管理和预防的知识。这种增强的意识鼓励个人寻求医疗建议并遵循处方治疗方案，最终导致更好的健康结果。此外，医疗专业人员的培训也越来越多，以有效识别和管理哮喘，这有助于改善患者护理。对患者教育的重视也促使了数字健康工具的发展，这些工具有助于监测和管理哮喘症状。随着意识的不断提高，对哮喘相关产品和服务的需求预计将上升，从而对哮喘疾病市场产生积极影响。

### 治疗选择的进展

治疗选择的进展是哮喘疾病市场的重要驱动因素。生物制剂和靶向疗法的引入改变了哮喘管理，为重症患者带来了新的希望。这些创新治疗方法，包括单克隆抗体，在临床试验中显示出良好的结果，改善了患者的预后并降低了医疗成本。生物制剂市场预计将大幅增长，估计在未来几年可能达到数十亿美元。随着医疗服务提供者越来越多地采用这些先进疗法，哮喘疾病市场可能会经历强劲增长，推动对更有效和个性化治疗方案的需求。

### 监测中的技术创新

监测哮喘症状的技术创新正在成为哮喘疾病市场的关键驱动因素。数字健康解决方案的整合，如移动应用程序和可穿戴设备，使患者能够实时跟踪他们的症状和用药情况。这些技术促进了患者与医疗提供者之间的更好沟通，从而实现更个性化的护理。数字健康解决方案的市场正在迅速扩展，预计在未来几年将显著增长。随着患者通过这些工具更加积极地参与哮喘管理，相关产品和服务的需求可能会增加。这一趋势强调了技术在改善哮喘护理中的重要性，并代表了哮喘疾病市场内的一个重要增长机会。

### 监管支持和政策倡议

监管支持和政策倡议在塑造哮喘疾病市场中发挥着至关重要的作用。各国政府和卫生组织越来越认识到哮喘是公共卫生的优先事项，这导致实施旨在改善哮喘护理的政策。这些倡议通常包括对研究的资助、对哮喘药物的补贴以及制定哮喘管理的指导方针。这些支持措施不仅增强了治疗的可及性，还鼓励制药公司投资于新疗法的开发。监管框架与患者和医疗服务提供者需求的一致性可能会促进哮喘疾病市场的创新和增长，因为利益相关者共同努力应对哮喘带来的挑战。

### 哮喘的发病率不断增加

哮喘的日益普遍是哮喘疾病市场的一个关键驱动因素。根据最近的估计，全球约有3亿人受到哮喘的影响，预计由于城市化和环境变化，这一数字将继续上升。这种患病率的增加需要对有效治疗方案和管理策略的更大需求。对哮喘作为一种慢性病的日益关注导致了旨在改善患者结果的医疗保健倡议的增强。因此，制药公司正在投资于研究和开发，以创造创新疗法，从而扩大其市场存在。哮喘对医疗保健系统的日益负担进一步强调了对有效解决方案的需求，使其成为哮喘疾病市场增长的一个关键因素。

## Future Outlook

哮喘疾病市场预计将在2024年至2035年间以3.52%的年均增长率增长，推动因素包括治疗选择的进步、意识的提高和发病率的上升。

**New opportunities:**

- 开发个性化吸入器技术以增强患者依从性。 扩展远程哮喘管理的远程医疗服务。 投资于基于人工智能的预测分析以预防哮喘发作。

到2035年，哮喘疾病市场预计将保持强劲，反映出持续的增长和创新。

## Segment Insights

### 按治疗类型：控制药物（最大）与生物制剂（增长最快）

在哮喘疾病市场中，治疗类型细分市场具有多样化的选择，包括控制药物、急救药物、生物制剂和联合疗法。在这些选项中，控制药物占据了最大的市场份额，提供长期控制和预防，而生物制剂由于其针对哮喘病理特定途径的创新机制，正迅速成为增长最快的细分市场。随着患者和医疗服务提供者越来越认识到维持哮喘控制的重要性，对控制药物的需求依然强劲。同时，哮喘的发病率上升以及对精准医疗的日益关注正在推动生物制剂细分市场的显著增长。对个性化治疗方法的日益关注进一步支持了生物制剂的扩展，使其在未来市场动态中成为关键参与者。

控制药物（主导）与联合疗法（新兴）

控制药物在哮喘管理中发挥着主导作用，通过皮质类固醇和其他抗炎药物提供长期控制。这些疗法对于预防加重和改善患者的生活质量至关重要。该细分市场拥有良好的市场存在，得到了广泛的临床数据和治疗指南的支持。另一方面，联合疗法，包括将吸入性皮质类固醇与长效β激动剂结合的疗法，正在成为一个重要的市场参与者。这种治疗方法不仅简化了患者的哮喘管理，还通过减少用药频率提高了依从性。这些疗法的整合反映了针对哮喘患者特定需求的个性化治疗方案日益增长的趋势。

### 按哮喘原因：过敏性哮喘（最大）与运动诱发性哮喘（增长最快）

哮喘疾病市场主要受到哮喘原因的影响，其中过敏性哮喘因其在大众中的普遍性而占据最大份额。过敏性哮喘发生在免疫系统对过敏原过度反应时，是导致哮喘症状的主要原因，影响着数百万人。相比之下，运动诱发性哮喘虽然不如过敏性哮喘普遍，但随着人们意识的提高，尤其是在寻求有效管理策略以控制运动期间症状的运动员和健身爱好者中，正在迅速增长。

过敏性哮喘（显性）与运动诱发性哮喘（新兴）

过敏性哮喘仍然是哮喘市场的主要原因，这得益于对过敏原的日益关注和诊断能力的提高，从而导致更高的识别和管理率。它的特点是对花粉、尘螨和宠物皮屑等环境触发因素的过度反应。与此同时，运动诱发性哮喘正成为运动员和身体活跃个体的重要关注点，显示出对专业治疗和预防措施的需求。这个细分市场受到健身和体育活动日益增长的趋势的推动，促使哮喘管理选项的进步，特别是针对进行剧烈身体活动的个体量身定制的选项。

### 按严重程度：中度持续（最大）与重度持续（增长最快）

在哮喘疾病市场中，各个细分市场显示出轻度间歇性和轻度持续性病例的明显流行，但中度持续性哮喘则是最大的细分市场。该人群的显著份额反映出一个稳定的患者群体，这一人群在塑造治疗方案和医疗资源分配中至关重要。尽管重度持续性类别较小，但它是增长最快的细分市场，受到意识提高、诊断技术改善以及各类人群中重度哮喘病例发生率上升的推动。

轻度间歇性（主导）与重度持续性（新兴）

轻度间歇性哮喘被认为是主要的细分市场，因为它在哮喘患者中广泛存在，通常以偶发症状和不频繁需要用药为特征。然而，值得注意的是，重度持续性哮喘正成为一个关键的关注领域，因为其复杂的管理需求以及对患者生活质量带来的重大挑战。重度持续性病例的日益增加凸显了对新疗法的迫切需求和针对性管理策略的发展，推动了这一细分市场的创新和投资。

### 按年龄组：儿童（最大）与成人（增长最快）

在哮喘疾病市场中，年龄组细分展示了多样的分布，儿童占据了最大的份额。由于环境诱因和遗传易感性等因素，这一人群特别容易受到哮喘的影响。紧随儿童之后，成年人在市场中占据了重要部分，在增长潜力方面超越了其他群体，因为他们越来越寻求有效的管理解决方案。老年人细分市场虽然在市场份额上较小，但由于老年人群中慢性呼吸道疾病的普遍存在，也发挥着至关重要的作用。该市场的增长趋势受到对不同年龄组哮喘影响的日益关注的推动。随着环境污染物的增加和生活方式的变化，导致成人哮喘诊断激增，成人细分市场正经历最快的增长。此外，治疗创新、儿童哮喘管理教育以及对老年人的宣传正在增强意识和治疗可及性，推动市场向前发展。

儿童（主导）与老年人（新兴）

儿童群体的哮喘发病率较高，通常与过敏原和呼吸道感染有关。该年龄段需要专业护理，包括儿科配方和哮喘管理教育，使其成为市场的主导力量。相比之下，老年群体被归类为新兴市场，因老年人群中哮喘发病率的增加而受到关注，通常伴随有慢性阻塞性肺病等合并症。随着医疗系统的发展以适应这一人群，针对老年人的个性化治疗和预防措施的关注也在不断演变，使其在整体哮喘疾病市场中成为一个增长的细分市场。

## Regional Market Share Analysis

哮喘疾病市场在2023年实现了244.6亿美元的估值，各个地区的贡献显著。北美占据了大部分市场份额，估值为105亿美元，预计到2032年将增长至142亿美元，主要受益于先进的医疗基础设施和日益增加的哮喘患病率。

欧洲紧随其后，2023年的估值为68亿美元，预计将增长至92亿美元，反映出对哮喘的认识和治疗采用的增加。亚太地区在2023年的估值为45亿美元，预计将达到61亿美元，得益于人口增长和医疗支出的增加。与此同时，南美和中东非洲展示了较小但重要的市场，2023年的估值分别为13亿美元和13.6亿美元。它们的增长潜力源于改善医疗服务的可及性和哮喘患病率的上升。

在这些地区，哮喘疾病市场的收入趋势表明，持续关注治疗和管理的创新，以及应对导致哮喘的环境因素。

**来源：初步研究、二次研究、MRFR数据库和分析师评审**

## Competitive Benchmarking

哮喘疾病市场的特点是动态的竞争格局，受到发病率上升和对创新治疗方案日益重视的驱动。主要参与者如葛兰素史克（GB）、阿斯利康（GB）和勃林格殷格翰（DE）处于前沿，各自采取不同的策略以增强市场定位。葛兰素史克（GB）专注于扩展其生物制剂产品组合，而阿斯利康（GB）则强调其在研究和开发方面的承诺，特别是在个性化医疗领域。勃林格殷格翰（DE）利用其在呼吸治疗方面的专业知识来加强其市场存在，表明整体上向创新和以患者为中心的解决方案的转变正在塑造竞争环境。

在商业策略方面，各公司越来越多地本地化制造和优化供应链，以提高效率和对市场需求的响应。哮喘疾病市场的竞争结构似乎适度分散，几家主要参与者施加影响。这种分散性允许多样化的治疗选择，但这些主要公司的集体策略创造了强大的竞争动态，推动了治疗和患者护理的进步。

在2025年8月，阿斯利康（GB）宣布与一家领先的数字健康公司建立战略合作伙伴关系，以将人工智能驱动的解决方案整合到其哮喘管理程序中。这一合作旨在增强患者参与度和对治疗方案的遵循，反映了医疗保健数字化的更广泛趋势。这一举措的战略重要性在于其改善患者结果和简化哮喘管理的潜力，使阿斯利康在创新护理解决方案中处于领先地位。

在2025年9月，葛兰素史克（GB）推出了一款新型吸入器，采用先进技术为患者提供关于其吸入技巧的实时反馈。这一举措不仅强调了公司对创新的承诺，还解决了哮喘管理的一个关键方面——正确使用吸入器。通过增强患者教育和遵循，葛兰素史克（GB）旨在减少加重发作并改善整体健康结果，从而巩固其在市场中的竞争优势。

在2025年7月，勃林格殷格翰（DE）扩大了其针对重度哮喘的新型生物治疗的临床试验计划。这一扩展反映了公司关注满足未满足的医疗需求并推进难治性哮喘患者的治疗选择。这一举措的战略意义在于其通过提供针对特定患者群体的创新疗法来捕获更大市场份额的潜力，从而增强勃林格殷格翰的竞争定位。

截至2025年10月，哮喘疾病市场的当前趋势表明，向数字化、可持续性和在治疗方案中整合人工智能的明显转变。战略联盟越来越多地塑造着市场格局，促进创新并增强患者护理。展望未来，竞争差异化可能会从传统的基于价格的竞争演变为关注技术进步、创新疗法和可靠的供应链，最终导致改善患者结果和更可持续的市场环境。

## Recent News & Developments

- **2024年第二季度：阿斯利康的Airsupra哮喘药物获得美国FDA批准** 阿斯利康和Avillion宣布，美国食品药品监督管理局批准了Airsupra（沙丁胺醇/布地奈德），这是一种新的哮喘救援吸入器，标志着该公司呼吸系统产品组合的重要补充。
- **2024年第二季度：葛兰素史克获得欧盟委员会对Trelegy Ellipta在儿童哮喘中的批准** 葛兰素史克宣布，欧盟委员会批准了Trelegy Ellipta用于治疗6至11岁儿童的哮喘，扩展了该药物在欧盟的标签。
- **2024年第一季度：安进和阿斯利康宣布FDA批准TEZSPIRE®（tezepelumab-ekko）用于重度哮喘的自我给药** 安进和阿斯利康获得FDA批准，推出一种新的预填充一次性笔，供重度哮喘患者在家自我给药生物治疗TEZSPIRE。
- **2024年第二季度：赛诺菲和再生元的Dupixent®获得FDA批准，成为首个用于1至11岁儿童的生物制剂，治疗嗜酸性哮喘** 赛诺菲和再生元宣布，Dupixent获得FDA批准，适用于1至11岁儿童的嗜酸性哮喘，成为美国首个针对该年龄组的生物制剂。
- **2024年第一季度：Propeller Health和诺华宣布合作，将数字健康平台与哮喘吸入器整合** Propeller Health和诺华达成合作，将Propeller的数字健康平台与诺华的哮喘吸入器整合，旨在改善用药依从性和患者结果。
- **2024年第二季度：BioMed X与勃林格殷格翰启动新研究项目，开发新型哮喘疗法** BioMed X和勃林格殷格翰宣布启动一项联合研究项目，专注于发现新的哮喘治疗方法。
- **2024年第一季度：Pulmatrix宣布PUR1900在哮喘的第二阶段研究中取得积极的顶线结果** Pulmatrix报告了其第二阶段临床试验的积极顶线结果，评估PUR1900（一种吸入性抗真菌药物）在哮喘患者中的应用，支持该候选药物的进一步开发。
- **2024年第二季度：Vectura Fertin Pharma在英国开设新的吸入制造设施** Vectura Fertin Pharma宣布在英国Chippenham开设新的制造设施，专门生产吸入疗法，包括哮喘治疗。
- **2024年第一季度：Kinaset Therapeutics完成4500万美元B轮融资，以推进哮喘药物候选者** Kinaset Therapeutics完成了一轮4500万美元的B轮融资，以支持其主要哮喘药物候选者KN-002的临床开发。
- **2024年第二季度：Verona Pharma的ensifentrine获得CHMP对COPD和哮喘维持治疗的积极意见** Verona Pharma宣布，欧洲药品管理局人用药品委员会（CHMP）对ensifentrine发表了积极意见，支持其用于COPD和哮喘的维持治疗的批准。
- **2024年第一季度：阿斯利康和霍尼韦尔合作开发具有近零全球变暖潜力的下一代吸入器** 阿斯利康和霍尼韦尔宣布合作，开发用于哮喘和COPD的下一代吸入器，采用霍尼韦尔的近零全球变暖潜力推进剂。
- **2024年第二季度：安进任命新的呼吸和炎症研发负责人** 安进宣布任命一位新高管，负责其呼吸和炎症研究与开发部门，监督公司的哮喘和过敏产品线。

## Report Scope

| 2024年市场规模 | 262.2（十亿美元） |
| --- | --- |
| 2025年市场规模 | 271.4（十亿美元） |
| 2035年市场规模 | 383.6（十亿美元） |
| 复合年增长率（CAGR） | 3.52%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 数字健康技术的整合增强了哮喘疾病市场的患者管理。 |
| 主要市场动态 | 哮喘的发病率上升推动了对创新疗法和治疗方案监管适应的需求。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 截至2024年，哮喘疾病市场的当前估值是多少？**
A: 2024年哮喘疾病市场的估值为262.2亿美元。

**Q: 2035年哮喘疾病市场的预计市场估值是多少？**
A: 预计到2035年，市场将达到383.6亿美元。

**Q: 在2025年至2035年的预测期内，哮喘疾病市场的预期CAGR是多少？**
A: 2025年至2035年期间，哮喘疾病市场的预期CAGR为3.52%。

**Q: 2024年哪个治疗类型细分的估值最高？**
A: 在2024年，控制药物部门的估值最高，达120亿美元。

**Q: 到2035年，生物制药部门的预计值是多少？**
A: 生物制剂部门预计到2035年将达到100亿美元。

**Q: 2024年过敏性哮喘的市场估值与非过敏性哮喘相比如何？**
A: 在2024年，过敏性哮喘的市场估值为100亿美元，而非过敏性哮喘的估值为80亿美元。

**Q: 预计到2035年，哪个年龄组的市场估值最高？**
A: 到2035年，成人年龄组的市场估值预计将达到180亿美元。

**Q: 到2035年，严重持续性哮喘的预计市场规模是多少？**
A: 到2035年，严重持续性哮喘的市场规模预计将达到148.6亿美元。

**Q: 哪些关键参与者正在主导哮喘疾病市场？**
A: 哮喘疾病市场的主要参与者包括葛兰素史克、阿斯利康和默克公司。

**Q: 2024年至2035年，联合疗法领域的预期增长趋势是什么？**
A: 组合疗法细分市场预计将从2024年的72.2亿美元增长到2035年的93.6亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/asthma-disease-market-34260*